Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
SRPT

SRPT - Sarepta Therapeutics Inc Stock Price, Fair Value and News

136.46USD+1.68 (+1.25%)Market Closed
Watchlist

Market Summary

USD136.46+1.68
Market Closed
1.25%

SRPT Alerts

  • JANUS HENDERSON GROUP PLC reported owning 5.7% of SRPT [2024-02-13]

SRPT Stock Price

View Fullscreen

SRPT RSI Chart

SRPT Valuation

Market Cap

12.8B

Price/Earnings (Trailing)

-18.48

Price/Sales (Trailing)

11.55

EV/EBITDA

-20.38

Price/Free Cashflow

-21.14

SRPT Price/Sales (Trailing)

SRPT Profitability

EBT Margin

-59.89%

Return on Equity

-90.39%

Return on Assets

-22.22%

Free Cashflow Yield

-4.73%

SRPT Fundamentals

SRPT Revenue

Revenue (TTM)

1.1B

Rev. Growth (Yr)

44.1%

Rev. Growth (Qtr)

27.02%

SRPT Earnings

Earnings (TTM)

-690.9M

Earnings Growth (Yr)

84.12%

Earnings Growth (Qtr)

-71%

Breaking Down SRPT Revenue

Last 7 days

6.1%

Last 30 days

15.3%

Last 90 days

61.9%

Trailing 12 Months

11.8%

How does SRPT drawdown profile look like?

SRPT Financial Health

Current Ratio

5.44

Debt/Equity

0

Debt/Cashflow

-371.54

SRPT Investor Care

Shares Dilution (1Y)

6.57%

Diluted EPS (TTM)

-7.83

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023975.7M1.0B1.1B0
2022765.8M835.2M876.0M933.0M
2021573.4M600.1M645.6M701.9M
2020407.5M450.2M495.1M540.1M
2019323.4M344.6M365.1M380.8M
2018202.8M241.4M273.9M301.0M
201737.9M70.3M102.7M154.6M
20162.3M3.3M4.4M5.4M
20157.6M5.5M3.4M1.3M
201415.8M15.5M12.4M9.8M
201330.6M22.3M18.9M14.2M
201243.9M43.5M43.6M37.3M
201142.5M50.1M48.9M47.0M
201020.5M23.5M26.5M29.4M
200900017.6M

Tracking the Latest Insider Buys and Sells of Sarepta Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 01, 2023
arif bilal
sold (taxes)
-295,812
80.34
-3,682
chief tech ops officer
Nov 17, 2023
rodino-klapac louise
sold (taxes)
-374,074
82.98
-4,508
head of r&d, cso
Nov 03, 2023
barry richard
bought
788,100
78.81
10,000
-
Nov 03, 2023
ingram douglas s
bought
2,001,800
79.3578
25,225
president & ceo
Nov 03, 2023
barry richard
bought
3,152,400
78.81
40,000
-
Nov 03, 2023
behrens m kathleen
acquired
435,450
29.03
15,000
-
Aug 14, 2023
chambers michael andrew
bought
1,092,430
109
9,979
-
Aug 11, 2023
chambers michael andrew
bought
2,559,270
108
23,686
-
Aug 10, 2023
chambers michael andrew
bought
3,701,070
106
34,867
-
Aug 04, 2023
wigzell hans lennart rudolf
acquired
435,450
29.03
15,000
-

1–10 of 50

Which funds bought or sold SRPT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 20, 2024
Quarry LP
new
-
24,108
24,108
-%
Feb 20, 2024
EVENTIDE ASSET MANAGEMENT, LLC
reduced
-27.25
-6,263,400
8,603,390
0.14%
Feb 20, 2024
Able Wealth Management LLC
new
-
2,411
2,411
-%
Feb 16, 2024
O'Dell Group, LLC
new
-
1,929
1,929
-%
Feb 16, 2024
BLUEFIN CAPITAL MANAGEMENT, LLC
sold off
-100
-1,577,680
-
-%
Feb 16, 2024
SECURITY NATIONAL BANK OF SO DAK
sold off
-100
-242,440
-
-%
Feb 16, 2024
Clarity Asset Management, Inc.
new
-
2,411
2,411
-%
Feb 16, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
reduced
-6.69
-1,253,640
3,612,360
0.01%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
reduced
-2.55
-186,000
640,000
0.05%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
reduced
-65.00
-1,749
675
-%

1–10 of 36

Are Funds Buying or Selling SRPT?

Are funds buying SRPT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SRPT
No. of Funds

Unveiling Sarepta Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
janus henderson group plc
5.7%
5,345,785
SC 13G/A
Feb 13, 2024
vanguard group inc
9.42%
8,816,124
SC 13G/A
Feb 09, 2024
capital international investors
5.1%
4,741,485
SC 13G
Jan 26, 2024
blackrock inc.
6.7%
6,266,973
SC 13G/A
Feb 14, 2023
sands capital management, llc
2.5%
2,151,378
SC 13G/A
Feb 10, 2023
janus henderson group plc
6.9%
6,028,016
SC 13G/A
Feb 09, 2023
vanguard group inc
9.15%
8,033,264
SC 13G/A
Feb 01, 2023
blackrock inc.
6.3%
5,557,234
SC 13G/A
Feb 14, 2022
sands capital management, llc
6.16%
5,364,627
SC 13G
Feb 11, 2022
janus henderson group plc
8.3%
7,245,862
SC 13G

Recent SEC filings of Sarepta Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G
Major Ownership Report
Jan 26, 2024
SC 13G/A
Major Ownership Report
Jan 08, 2024
8-K
Current Report
Dec 05, 2023
4
Insider Trading
Nov 20, 2023
4
Insider Trading

Peers (Alternatives to Sarepta Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.8B
6.8B
-16.59% -47.80%
-7.82
5.38
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.9B
1.8B
-23.99% -31.71%
-45.13
10.87
76.23% 61.08%
17.2B
2.3B
-4.89% -18.90%
116.89
7.44
15.05% 75.21%
13.6B
3.7B
-7.62% -26.87%
22.76
3.68
8.87% 75.42%
MID-CAP
8.1B
272.9M
-2.06% 34.31%
-13.4
29.75
141.38% 4.43%
6.0B
-
-3.85% 226.12%
-9.54
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.34
6.44
23.54% 31.53%
3.9B
240.7M
-19.08% -10.99%
-13.19
16.26
-1.03% -92.09%
3.7B
270.6M
8.92% 47.81%
-15.63
13.81
440.80% -27.84%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
24.15
4.3
81.69% -7.29%
629.6M
1.0B
-9.17% -57.89%
-1.15
0.6
-43.15% 58.48%
179.0M
4.9M
-14.18% -58.18%
-1.09
36.62
-57.57% 50.48%
114.7M
881.7K
289.54% 381.25%
-2.42
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Sarepta Therapeutics Inc News

Latest updates
MarketBeat10 hours ago
The Motley Fool16 Feb 202404:23 pm
Seeking Alpha09 Jan 202408:00 am
The Wall Street Journal3 months ago

Sarepta Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue27.0%331,817,000261,238,000253,500,000258,427,000230,269,000233,487,000210,830,000201,461,000189,406,000164,089,000146,931,000145,138,000143,924,000137,363,000113,674,000100,113,00099,041,00094,668,00087,011,00084,415,00078,486,000
Costs and Expenses-10.7%352,659,000394,757,000391,588,000365,260,000361,624,000444,619,000297,711,000307,274,000223,864,000331,663,000298,796,000315,854,000280,992,000275,716,000231,700,000330,332,000222,631,000370,035,000163,398,000223,778,000148,585,000
  S&GA Expenses2.0%120,893,000118,564,000110,714,000120,478,000104,787,000154,316,00071,840,00078,055,00061,127,00072,347,00071,131,00086,046,00075,373,00073,688,00082,768,00081,424,00075,429,00067,393,00060,566,00064,220,00053,044,000
  R&D Expenses------------------113,266,00090,553,000146,207,00086,584,000
EBITDA Margin33.3%-0.54-0.81-1.04-0.65-0.70-0.48-0.34-0.46-0.61-0.93-1.10-0.91---------
Interest Expenses820.9%7,312,000794,0007,023,0003,145,00013,493,00016,092,00011,688,00016,222,00011,947,00016,092,00011,688,00013,956,0005,430,0009,647,0005,385,0004,275,000---4,447,000803,000
Income Taxes-17.0%7,763,0009,355,0004,045,0007,938,0001,320,0003,388,000879,00092,000237,000-354,000-143,000832,00096,00020,000115,000711,000226,000174,00084,000-779,000-674,000
Earnings Before Taxes-127.5%-33,174,000-14,585,000-512,710,000-101,306,000-256,418,000-228,093,000-104,146,000-121,889,000-47,907,000-81,759,000-167,393,000-188,485,000-196,403,000-150,800,000-17,377,000-234,992,000-126,100,000-276,229,000-76,559,000-141,674,000-77,067,000
EBT Margin32.1%-0.60-0.88-1.13-0.74-0.81-0.60-0.46-0.60-0.75-1.06-1.23-1.02---------
Net Income-71.0%-40,937,000-23,940,000-516,755,000-109,244,000-257,738,000-231,481,000-105,025,000-121,981,000-48,144,000-81,405,000-167,250,000-189,317,000-196,499,000-150,820,000-17,492,000-235,703,000-126,326,000-276,403,000-76,643,000-140,895,000-76,393,000
Net Income Margin30.9%-0.63-0.90-1.14-0.75-0.82-0.61-0.47-0.60-0.75-1.06-1.23-1.03---------
Free Cashflow-3.0%-144,379,000-140,143,000-218,881,000-100,356,000-73,195,000-75,893,000-106,726,000-31,532,000-133,570,000-115,040,000-201,520,000-203,145,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-0.5%3,1103,1263,0603,1283,1562,9973,0563,1482,6622,7592,7652,9852,7812,8832,9471,8231,7021,7481,9641,6421,183
  Current Assets-0.9%2,4512,4732,4882,5582,6262,4692,5312,6042,1852,2652,2712,4852,3232,4592,5471,4691,3621,4271,6711,4261,012
    Cash Equivalents-36.4%5428528729671,0398691,2342,1161,5991,6971,4821,5031,4751,6401,764835725809732371210
  Inventory7.6%244227203204221208199186288269240232220180173171166157140125116
  Net PPE12.4%21218918318018118318719119920320319017215313713012011710697.0077.00
Liabilities-1.6%2,3452,3842,3472,7432,7252,2702,1992,2202,1932,2742,2302,2231,8891,8401,8031,005707649615610543
  Current Liabilities-9.6%451499537620603546455453373425365416378355306265216162137174114
Shareholder's Equity3.1%7647417133854317268579284704855357628921,0431,1458189951,0991,3491,032640
  Retained Earnings-0.9%-4,491-4,450-4,426-3,910-3,800-3,543-3,311-3,206-3,084-3,036-2,955-2,848-2,658-2,462-2,311-2,294-2,058-1,931-1,655-1,578-1,438
  Additional Paid-In Capital1.2%5,2575,1935,1404,2974,2354,2724,1694,1353,5543,5223,4913,6103,5513,5053,4563,1123,0533,0313,0042,6112,078
Accumulated Depreciation-----------------45.0038.0033.0028.0025.00
Shares Outstanding0.3%94.0093.0093.0088.0087.0087.0087.0087.0080.0080.0080.0078.00---------
Float------6,561,646---6,206---12,576---11,294---
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations6.2%-114-122-209-92.39-64.96-66.81-101-29.33-124-109-180-174-238-107628-163-67.43-79.00-146-122-113
  Share Based Compensation1.4%48.0047.0041.0051.0050.0010329.0030.0027.0029.0029.0030.0027.0028.0024.0022.0021.0020.0016.0013.0011.00
Cashflow From Investing-317.9%-21097.0012.0010.0019.00-289-785-2.5820.00321157-12354.00-34.22-17.6817.00-17.96152135-237-63.40
Cashflow From Financing162.8%15.006.0010211.002160.005.005496.004.003.0032719.0018.003192572.006.00378521-23.95

SRPT Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:    
Products, net$ 309,322$ 207,774$ 779,805$ 607,836
Type of Revenue [Extensible List]us-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMember
Collaboration$ 22,495$ 22,495$ 66,750$ 66,750
Total revenues331,817230,269846,555674,586
Cost and expenses:    
Cost of sales (excluding amortization of in-licensed rights)37,02639,952106,167109,190
Research and development194,301216,707681,870663,286
Selling, general and administrative120,893104,787350,171330,943
Amortization of in-licensed rights439178796535
Total cost and expenses352,659361,6241,139,0041,103,954
Operating loss(20,842)(131,355)(292,449)(429,368)
Other loss, net:    
Gain from sale of Priority Review Voucher00102,0000
Loss on debt extinguishment0(125,441)(387,329)(125,441)
Other income (expense), net(12,332)37817,309(33,848)
Total other (loss), net(12,332)(125,063)(268,020)(159,289)
Loss before income tax expense (benefit)(33,174)(256,418)(560,469)(588,657)
Income tax expense (benefit)7,7631,32021,1635,587
Net loss(40,937)(257,738)(581,632)(594,244)
Other comprehensive income (loss):    
Unrealized gains (losses) on investments, net of tax417(720)1,026(3,185)
Total other comprehensive income (loss)417(720)1,026(3,185)
Comprehensive loss$ (40,520)$ (258,458)$ (580,606)$ (597,429)
Net loss per share - basic$ (0.46)$ (2.94)$ (6.56)$ (6.79)
Net loss per share - diluted$ (0.46)$ (2.94)$ (6.56)$ (6.79)
Weighted average number of shares of common stock used in computing basic and diluted net loss per share88,88987,62888,60987,465
Weighted average number of shares of common stock used in computing basic and diluted net loss per share88,88987,62888,60987,465

SRPT Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents, Fair value$ 541,932$ 966,777
Short-term investments1,191,6101,022,597
Accounts receivable318,855214,628
Inventory244,011203,968
Other current assets154,441149,891
Total current assets2,450,8492,557,861
Property and equipment, net212,367180,037
Right of use assets133,45464,954
Non-current inventory176,112162,545
Other non-current assets136,925162,969
Total assets3,109,7073,128,366
Current liabilities:  
Accounts payable87,94895,875
Accrued expenses322,350418,996
Deferred revenue, current portion22,49489,244
Other current liabilities17,95115,489
Total current liabilities450,743619,604
Long-term debt1,236,7551,544,292
Lease liabilities, net of current portion134,75257,578
Deferred revenue, net of current portion485,000485,000
Contingent consideration38,10036,900
Other non-current liabilities042
Total liabilities2,345,3502,743,416
Commitments and contingencies (Note 16)
Stockholders’ equity:  
Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding00
Common stock, $0.0001 par value, 198,000,000 shares authorized; 93,537,355 and 87,950,117 issued and outstanding at September 30, 2023, and December 31, 2022, respectively99
Additional paid-in capital5,256,8544,296,841
Accumulated other comprehensive loss, net of tax(638)(1,664)
Accumulated deficit(4,491,868)(3,910,236)
Total stockholders’ equity764,357384,950
Total liabilities and stockholders’ equity$ 3,109,707$ 3,128,366
SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEwww.sarepta.com
 EMPLOYEES1162

Sarepta Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Sarepta Therapeutics Inc? What does SRPT stand for in stocks?

SRPT is the stock ticker symbol of Sarepta Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sarepta Therapeutics Inc (SRPT)?

As of Fri Feb 23 2024, market cap of Sarepta Therapeutics Inc is 12.77 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SRPT stock?

You can check SRPT's fair value in chart for subscribers.

What is the fair value of SRPT stock?

You can check SRPT's fair value in chart for subscribers. The fair value of Sarepta Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sarepta Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SRPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sarepta Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SRPT is over valued or under valued. Whether Sarepta Therapeutics Inc is cheap or expensive depends on the assumptions which impact Sarepta Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SRPT.

What is Sarepta Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Feb 23 2024, SRPT's PE ratio (Price to Earnings) is -18.48 and Price to Sales (PS) ratio is 11.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SRPT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Sarepta Therapeutics Inc's stock?

In the past 10 years, Sarepta Therapeutics Inc has provided 0.178 (multiply by 100 for percentage) rate of return.